{"id":"NCT02195232","sponsor":"Jeffrey Zwicker, MD","briefTitle":"Cancer Associated Thrombosis and Isoquercetin (CATIQ)","officialTitle":"Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-01","primaryCompletion":"2018-12","completion":"2019-10-22","firstPosted":"2014-07-21","resultsPosted":"2019-11-12","lastUpdate":"2021-03-03"},"enrollment":64,"design":{"allocation":"NON_RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Thromboembolism of Vein VTE in Colorectal Cancer","Thromboembolism of Vein in Pancreatic Cancer","Thromboembolism of Vein in Non-small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Isoquercetin","otherNames":["quercetin-3-O-glucoside","482-35-9"]}],"arms":[{"label":"Cohort A - Isoquercetin","type":"EXPERIMENTAL"},{"label":"Cohort B - Isoquercetin","type":"EXPERIMENTAL"}],"summary":"This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.","primaryOutcome":{"measure":"Percent Change in D-dimer Value","timeFrame":"Baseline, 56 Day","effectByArm":[{"arm":"Cohort A (Isoquercetin 500 mg)","deltaMin":9.9,"sd":null},{"arm":"Cohort B (Isoquercetin 1000 mg)","deltaMin":-21.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.92"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":12},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":["30652973"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":28},"commonTop":["Diarrhea","Nausea","Gastrointestinal","Constipation","Epistaxis"]}}